• On Wednesday, May 16 from 2:00 p.m. to 4:00 p.m. in the Theatre Bordeaux, William Wijns, M.D., and Martin B. Leon, M.D., will chair a “Tools and Techniques” session featuring two live transmissions of patients treated using the Tryton  stent by Eulogio Garcia, M.D., at the Hospital Clinico San Carlos in Madrid, Spain.

• On Thursday, May 17, at 11:22 a.m. in Room 341, Maik Grundeken, M.D., of the Department of Cardiology at the University of Amsterdam in the Netherlands, will present a patient-level pooled analysis of six-month clinical outcomes from more than 900 patients treated with the Tryton stent in eight post-marketing registries.

• In addition, the conference will feature more than 10 Tryton case reports and three abstracts presenting data related to the Tryton stent system.

The Tryton stent has now been used to treat approximately 5,000 patients and is commercially available throughout Europe, Russia and the Middle East. The company recently began enrollment in the first and only randomized controlled U.S. IDE pivotal clinical trial evaluating a dedicated bifurcation stent. The 704-patient study compares a Tryton stent in the side branch vs. the use of balloon angioplasty in the side branch, with both arms of the trial utilizing a standard drug eluting stent in the main vessel. The trial has completed its IVUS angiographic sub study cohorts and enrollment remains on schedule to complete enrolllment later this year. The results of the trial will be submitted to the U.S. Food and Drug Administration (FDA) for approval to market the device in the United States.

Clinical data presented on more than 1,000 patients treated with the Tryton stent has demonstrated consistent target lesion revascularization rates of less than four percent and low thrombosis rates at six-month follow up and beyond.

About Coronary Bifurcation Disease
Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches from another. Current approaches to treating these lesions are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis, the re-narrowing of the stented vessel following implantation. In patients undergoing PCI-stenting, approximately one-third have a bifurcation lesion. Left main disease, an accumulation of plaque that narrows the base of the coronary tree, is a persistent challenge in interventional cardiology, as more than 75 percent of left main lesions are bifurcation lesions.

About the Tryton Side Branch Stent
The Tryton Side Branch Stent System is built for bifurcation using proprietary Tri-zone™ technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel. The stent system has received CE Mark and is commercially available throughout Europe, Russia and the Middle East. It is approved in the United States for investigational use only.

About the Randomized Tryton IDE Pivotal Study
The landmark Tryton pivotal study is a multi-national randomized trial that compares a Tryton stent in the side branch vs. the use of balloon angioplasty in the side branch, with both arms of the trial utilizing a standard drug eluting stent in the main vessel. The study, which is the first and only randomized IDE pivotal clinical trial evaluating a dedicated bifurcation stent, will enroll 704 patients at up to 75 centers in North America, Europe and Israel. Martin Leon, M.D. (Columbia University, New York) serves as principal investigator for the study and Patrick Serruys (Thoraxcenter, Rotterdam) is leading IVUS and three-dimensional angiographic analysis.

About Tryton Medical, Inc.
Tryton Medical, Inc., located in Durham, N.C., is a leading developer of novel stent systems for the treatment of bifurcation lesions. The company was founded in 2003 by Aaron V. Kaplan, M.D.
(professor of medicine at Dartmouth Medical School/Dartmouth- Hitchcock Medical Center) and Dan Cole to develop stents for the definitive treatment of bifurcation lesions. Privately held, Tryton
is backed by Arnerich Massena & Associates, Spray Ventures, PTV Sciences, and RiverVest Ventures. For more information please visit www.trytonmedical.com.

# # #

Media Contact:

Nicole Osmer
(650) 454-0504

Cameron Health has developed a next-generation implantable defibrillator that is easier to implant and does not require leads that attach to the heart, as is necessitated by other defibrillators.

Cameron Health’s device is the world’s first and only commercially available subcutaneous implantable cardioverter defibrillator, called the S-ICD® System. Unlike conventional implantable cardioverter defibrillators (ICDs), which require thin, insulated wires (leads) to pass through the venous system and into the heart, the entire S-ICD System sits just below the skin and leaves the heart and blood vessels untouched. This one-of-a-kind technology has the potential to expand the reach of ICD therapy, offering physicians and appropriate patients a new alternative to traditional ICDs, while strengthening Boston Scientific’s arrhythmia management portfolio.

The agreement calls for an upfront payment of $150 million, payable upon transaction closing, an additional potential $150 million payment upon FDA approval of the S-ICD System, plus up to an additional $1.050 billion of potential payments upon achievement of specified revenue-based milestones over a six-year period following FDA approval.

To view Boston Scientific’s release, please visit http://bostonscientific.mediaroom.com/index.php?s=24889&item=124076

About RiverVest Venture Partners®

RiverVest Venture Partners is a venture capital firm focused on identifying and shaping early-stage life science companies throughout the U.S. to create significant shareholder value. With hands-on, high-level expertise and financial resources, RiverVest supports entrepreneurs by helping them achieve near-term objectives that position their companies for exit.

Since its inception in September 2000, RiverVest has raised two investment funds, with total committed capital of $164 million, and supported more than 25 innovative life science companies. For more information, please visit http://www.rivervest.com.

Media Contact
Callaway Zuccarello
Callaway & Company
314-862-4300

The conference will focus on MEMS technologies for biomedical applications, or BioMEMS, whose market size is estimated at $1.7 billion. BioMEMS, or the biological and biomedical applications of micro- and nanotechnology, is finding widespread applicability and uses in areas such as diagnostics, therapeutics and tissue engineering.

In addition to her role at RiverVest, Spilizewski is a leader of the medical device team at Cleveland-based BioEnterprise, an initiative to accelerate the growth of healthcare companies and the commercialization of bioscience technologies.

Over the past 20 years, Spilizewski has developed and commercialized products for medical devices and applications including wound care, diagnostics, surgical and electromedical applications. Spilizewski received her MBA, M.S. in Macromolecular Science and a B.S. degree in Biomedical Engineering from Case Western Reserve.

About RiverVest Venture Partners®

RiverVest Venture Partners is a venture capital firm focused on identifying and shaping early-stage life science companies throughout the U.S. to create significant shareholder value. With hands-on, high-level expertise and financial resources, RiverVest supports entrepreneurs by helping them achieve near-term objectives that position their companies for exit.

Since its inception in September 2000, RiverVest has raised two investment funds, with total committed capital of $164 million, and supported more than 25 innovative life science companies. For more information, please visit http://www.rivervest.com or follow @RiverVest on Twitter.

About BioEnterprise

BioEnterprise is a business formation, recruitment, and acceleration initiative designed to grow health care companies and commercialize bioscience technologies. Based in Cleveland, BioEnterprise’s founders and partners are Cleveland Clinic, University Hospitals, Case Western Reserve University, Summa Health System and BioInnovation Institute in Akron. For more information, please visit http://www.bioenterprise.com .